GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...

CAMP4 signs ASO collaboration with GSK, securing $17.5 million upfront as analysts reaffirm Outperform and highlight 2026 ...

Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and ...

CAMP4 Therapeutics is pioneering the development of antisense oligonucleotides (ASOs) that target regulatory RNAs (regRNAs). These molecules play a crucial role in gene expression and can influence ...

CAMP4 will apply its RAP Platform® to generate antisense oligonucleotide candidates, while GSK will lead development and ...

GSK has struck the collaboration to accelerate development of RNA-based therapies for neurodegenerative and renal disorders.

In a significant move towards advancing healthcare solutions, GSK has announced a partnership with Camp4 Therapeutics, a regulatory RNA biotech firm. This collaboration aims to discover and create new ...

Cambridge, USA-based CAMP4 Therapeutics has entered into a strategic research, collaboration and license agreement with UK ...

In a deal announced Thursday, CAMP4 said it will receive $17.5 million upfront from GSK and will be eligible for development and commercial milestone payments as well as tiered royalties on ...

CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an announcement. On December 17, 2025, CAMP4 Therapeutics entered into a strategic ...

Novo Nordisk's application for CagriSema comes at the same time as competitor Eli Lilly's ask for its obesity drug orforglipron. Elsewhere, Merck & Co. and Pfizer succeeded in a bladder cancer study.